Search
Close this search box.

IGC Pharma's novel approach to

Alzheimer's Disease

Reach out to learn more about IGC-AD1's Phase 2b trial for agitation in dementia due to Alzheimer's

Latest Press Release

June 10, 2024

Investigating the Impact of CYP2C9 Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

Alzheimer's disease affects over 55 million individuals worldwide 1

In treating agitation, which affects 40-80% of individuals with Alzheimer’s disease2, IGC-AD1 has shown promising results.

Before After

Drag to discover more

Impacting Lives: Our Work Matters

With no known cure for Alzheimer’s disease, our drugs have the potential to change lives. 

Million
0
Americans with Alzheimer’s disease in 20243
Million
0
Americans with Alzheimer’s disease by 20603

5th Leading

Cause of death among
Americans aged 65+3

Trillon
$ 0

Expected cost of Alzheimer’s and dementia by 2050 (in 2024 dollars) if no treatment or cure is found3

From the CEO's desk:
Vertical integration

Periodic updates and perspectives on various aspects of our business.

Science Spotlight

Welcome to “Science Spotlight” – your exclusive platform for insights into neurological disorders. Dr. Juan Manuel Orjuela and the IGC Pharma scientific team bring you in-depth articles on conditions such as Alzheimer’s disease, offering comprehensive updates on treatment and understanding their impact on individuals and families. Explore the roles of caregivers and dynamics within affected families. Stay informed with our latest article.

Hypertension as a risk factor for cognitive decline

Hypertension, or high blood pressure, significantly impacts public health worldwide. Hypertension is well recognized for its role in cardiovascular disease, revealing implications for cognitive decline and dementia. Increasing clinical evidence for the early detection, management, and prevention of this condition may provide insights into a more comprehensive patient care, a more effective prevention of cognitive decline, and an improvement of overall quality of life.

Raising the Voice:  A Comment on Race and Ethnic Disparities in Alzheimer’s Disease Clinical Research

Alzheimer's Disease clinical research has faced a significant challenge for a long time in achieving diverse racial or ethnic representation in clinical trials. Many of these issues are rooted in deeper structural problems that leave some populations apart from the scope of science. While much work remains to be done to address this subject, there is a growing demand for more representative clinical trial data.

Hypertension as a Risk Factor for Cognitive Decline

Hypertension, or high blood pressure, significantly impacts public health worldwide. Hypertension is well recognized for its role in cardiovascular disease, revealing implications for cognitive decline and dementia. Increasing clinical evidence for the early detection, management, and prevention of this condition may provide insights into a more comprehensive patient care, a more effective prevention of cognitive decline, and an improvement of overall quality of life.

IGC PHARMA Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively.

Psychosis in Parkinson

Parkinson's awareness month ____________________________ Parkinson’s disease psychosis is a neuropsychiatric complication that affects more than 20% of patients affected by Parkinson’s. Common symptoms involve visual or auditory hallucinations, distorted perception, and experiences. More challenging symptoms may occur in the form of delusions, which often cause agitation, aggressiveness, and affect the quality of life of the patient and their families.

IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer’s Research

By: Faith Ashmore Benzinga …

IGC Pharma Advances in Alzheimer’s Research from Pre-clinical Studies to Phase Two Trials with its Novel Therapy Candidate IGC-AD1

By:   Faith Ashmore …

Investors
Latest News

May 21, 2024

IGC Pharma to Attend BIO International Convention 2024

May 21, 2024

IGC Pharma to Attend BIO International Convention 2024

April 16, 2024

IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two

Investing in the Future: Building Brighter Lives for Children

At IGC Pharma, we recognize our commitment to patients, caregivers, and their families, including children. Explore our programs dedicated to children.

  1. World Health Organization, Dementia, Key facts, 15 March 2023.
  2. Van der Mussele S et al. Agitation-associated behavioral symptoms in MCI and Alzheimer’s dementia. Aging Ment Health 2014;19(3):247–57.
  3. Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5)